Amyotrophic lateral sclerosis (ALS) is tracked almost entirely through motor and respiratory measures — grip strength, breathing capacity, the ALSFRS-R functional rating scale. A retrospective cohort study published in BMC Medicine suggests sleep quality, measured at the time of diagnosis, deserves a place on that list too: patients with poor sleep had more than double the risk of reaching a combined endpoint of tracheostomy or death within three years.
Following 268 Patients From Diagnosis
The researchers, led by Jiang and colleagues, drew on an institutional ALS registry in China, enrolling 268 patients treated between January 2019 and May 2022. At baseline, each patient completed the Pittsburgh Sleep Quality Index (PSQI), a widely used self-report measure that scores sleep latency, duration, efficiency, and disturbances. Patients were then followed for up to 36 months, with the researchers tracking a composite endpoint of tracheostomy or all-cause death, whichever came first.
Over the follow-up period, 115 of the 268 patients — nearly 43% — reached that composite endpoint. The researchers used Cox proportional hazards models, adjusting for age, sex, household income, site of symptom onset, forced vital capacity, baseline ALSFRS-R score, disease progression rate, body mass index, albumin levels, and depression scores, to isolate sleep quality's independent association with the outcome.
A More Than Doubled Risk
Compared with patients who reported no sleep disturbance at diagnosis, those with moderate-to-severe sleep disturbance faced a 2.65-fold higher risk of tracheostomy or death (hazard ratio 2.65, 95% CI 1.55–4.53, p < 0.001). Patients with only mild sleep disturbance did not show a statistically significant increase in risk, suggesting the association concentrates specifically among the most severely sleep-disrupted patients rather than scaling smoothly across the whole range of PSQI scores. The researchers also used restricted cubic spline analysis to confirm the relationship held across subgroups and sensitivity checks.
Why Sleep and ALS Might Be Connected
ALS already disrupts sleep through multiple, well-documented routes: declining respiratory muscle strength can cause nocturnal hypoventilation and frequent awakenings, muscle cramps and immobility make it hard to stay comfortable through the night, and anxiety or depression related to a terminal diagnosis can independently fragment sleep. The study's authors adjusted for forced vital capacity, body mass index, and depression scores specifically to account for some of these overlapping pathways, and the sleep disturbance association held even after that adjustment.
That doesn't resolve the direction of the relationship. It's plausible that poor sleep is primarily a marker of more severe or faster-moving underlying disease rather than an independent contributor to decline — patients whose disease is progressing quickest may simply sleep the worst, for reasons the PSQI can't distinguish from respiratory decline or disease burden generally. The authors explicitly caution against reading their results as evidence that improving sleep would change the course of the disease, since this is observational data from a single registry rather than an interventional trial.
What This Means for Patients
For ALS patients and their care teams, this adds sleep quality to a growing list of factors — alongside respiratory function, nutritional status, and mood — worth monitoring closely after diagnosis, both because it may offer an early signal of a more aggressive disease course and because sleep disturbance is itself a target that can sometimes be addressed, whether through managing respiratory symptoms overnight, treating comorbid depression, or adjusting medications and sleep positioning for comfort.
The findings don't support sleep quality as a treatment target for altering ALS's trajectory on their own, and the study's single-center, retrospective design means it will need confirmation in other ALS populations before the size of the risk estimate can be taken as settled. But a self-report questionnaire that takes a few minutes to complete at diagnosis identifying a subgroup facing nearly triple the risk of a major clinical milestone is the kind of simple, low-cost signal that could help clinicians flag which newly diagnosed patients may need closer respiratory and functional monitoring sooner rather than later.
